Webinar Overview

The ADC pipeline and advanced antibody modalities are expanding rapidly, putting greater challenges on upstream timelines. Establishing a robust, high-performing cell line early is increasingly critical to keeping CMC on track and enabling downstream success. In this webinar, Dr. Jiawen Xu will outline AsymBio’s integrated, multi-site capabilities supporting antibody and ADC programs, introduce the AmigoCHO™ cell line development (CLD) platform, and share practical “CLD toolbox” strategies for common development bottlenecks. The session will conclude with case studies that highlight the philosophy of AysmBio on empowering global clients: Do the right things at the first time, and do them in right ways.

Key Learning Objectives

•  • Understand AsymBio’s capabilities as a partner for antibody and ADC development 

•  • Learn how the AmigoCHO™ CLD platform is applied in a standardized CLD workflow

•  • Identify CLD bottlenecks and toolbox strategies used to facilitate clone screening

•  • Take away practical lessons to increase your chances of success in CLD

Speaker 

Jiawen Xu, Ph.D.

Senior Director, Department of Cell Line Development & Center of Biological Technology and Innovation, AsymBio